Fine Gael MEP Seán Kelly is preparing to launch his bid to be president — once his family has given him the go-ahead. Mr Kelly told the Sunday Independent his time spent serving as president of ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price target of Yen4,200.00. The company’s shares closed ...

GREENSBORO, N.C. (AP) — No. 11 Duke has avenged two late-season losses in two days, and the Blue Devils will need another such result to secure their first ACC Tournament championship in 12 years.

Lecanemab is approved in the U.S.,8 Japan,9 China,10 South Korea,11 Hong Kong,12 Israel,13 the United Arab Emirates,14the United Kingdom,15 Mexico16, Macau and Oman. Eisai has submitted applications ...

It's too early to talk about sending troops to Ukraine, Riho Terras, Estonian MEP and vice-chair of the European Parliament committee on Defence, tells Euronews' Radio Schuman today. Two days ...

TOKYO and CAMBRIDGE, Mass., Mar 4, 2025 - (JCN Newswire) - - Eisai Co., Ltd. and Biogen Inc. announced today that the Therapeutic Goods Administration (TGA) of Australia has confirmed the initial ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink “Chocola BB® Nightwell” (designated quasi-drug product), a nutritional drink to help ...

(MENAFN- JCN NewsWire) "Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell" - Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Eisai Co., Ltd. has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor ...